In our study, we found that SIRPα blockade therapy inhibited PI3K/AKT signaling in myeloid cells to suppress the PD-L1 expression and polarization of TIMs to pro-tumor M2-like TAMs or G-MDSCs. Here, SIRPA is linked to neoplasm.